AU2005206290B2 - Thiazole derivatives as A2b antagonists - Google Patents

Thiazole derivatives as A2b antagonists Download PDF

Info

Publication number
AU2005206290B2
AU2005206290B2 AU2005206290A AU2005206290A AU2005206290B2 AU 2005206290 B2 AU2005206290 B2 AU 2005206290B2 AU 2005206290 A AU2005206290 A AU 2005206290A AU 2005206290 A AU2005206290 A AU 2005206290A AU 2005206290 B2 AU2005206290 B2 AU 2005206290B2
Authority
AU
Australia
Prior art keywords
formula
alkyl
alkoxy
compound according
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2005206290A
Other languages
English (en)
Other versions
AU2005206290A1 (en
Inventor
Neil John Press
Roger John Taylor
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=31971241&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2005206290(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis AG filed Critical Novartis AG
Publication of AU2005206290A1 publication Critical patent/AU2005206290A1/en
Application granted granted Critical
Publication of AU2005206290B2 publication Critical patent/AU2005206290B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2005206290A 2004-01-21 2005-01-20 Thiazole derivatives as A2b antagonists Ceased AU2005206290B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0401336.3 2004-01-21
GBGB0401336.3A GB0401336D0 (en) 2004-01-21 2004-01-21 Organic compounds
PCT/EP2005/000542 WO2005070926A1 (en) 2004-01-21 2005-01-20 Thiazole derivatives as a2b antagonists

Publications (2)

Publication Number Publication Date
AU2005206290A1 AU2005206290A1 (en) 2005-08-04
AU2005206290B2 true AU2005206290B2 (en) 2008-12-04

Family

ID=31971241

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2005206290A Ceased AU2005206290B2 (en) 2004-01-21 2005-01-20 Thiazole derivatives as A2b antagonists

Country Status (16)

Country Link
US (1) US20090233938A1 (enExample)
EP (1) EP1709036B1 (enExample)
JP (1) JP2007518767A (enExample)
KR (1) KR20060129276A (enExample)
CN (1) CN1910178B (enExample)
AT (1) ATE388147T1 (enExample)
AU (1) AU2005206290B2 (enExample)
BR (1) BRPI0506927A (enExample)
CA (1) CA2553010A1 (enExample)
DE (1) DE602005005161T2 (enExample)
ES (1) ES2300985T3 (enExample)
GB (1) GB0401336D0 (enExample)
PL (1) PL1709036T3 (enExample)
PT (1) PT1709036E (enExample)
RU (1) RU2374242C2 (enExample)
WO (1) WO2005070926A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2270715B1 (es) 2005-07-29 2008-04-01 Laboratorios Almirall S.A. Nuevos derivados de pirazina.
JP5341516B2 (ja) * 2005-09-13 2013-11-13 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ２−アニリン−４−アリール置換チアゾール誘導体
ES2274712B1 (es) 2005-10-06 2008-03-01 Laboratorios Almirall S.A. Nuevos derivados imidazopiridina.
MX2008011828A (es) * 2006-03-17 2008-09-29 Cv Therapeutics Inc Metodo para la prevencion y el tratamiento de enfermedad hepatica utilizando antagonistas del receptor de adenosina a2b.
WO2007134958A1 (en) * 2006-05-18 2007-11-29 F. Hoffmann-La Roche Ag Thiazolo-pyramidine / pyridine urea derivatives as adenosine a2b receptor antagonists
JO2784B1 (en) 2007-10-18 2014-03-15 شركة جانسين فارماسوتيكا ان. في 5,3,1 - Triazole substitute derivative
JP2011500625A (ja) 2007-10-18 2011-01-06 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ トリ置換された１，２，４−トリアゾール
NZ587669A (en) 2008-03-19 2011-07-29 Janssen Pharmaceutica Nv Trisubstituted 1, 2, 4 -triazoles as nicotinic acetylcholine receptor modulators
EP2280945B1 (en) 2008-05-09 2014-09-03 Janssen Pharmaceutica, N.V. Trisubstituted pyrazoles as acetylcholine receptor modulators
US9453002B2 (en) 2013-08-16 2016-09-27 Janssen Pharmaceutica Nv Substituted imidazoles as N-type calcium channel blockers
ES2580702B1 (es) 2015-02-25 2017-06-08 Palobiofarma, S.L. Derivados de 2-aminopiridina como antagonistas del receptor A2b de adenosina y ligandos del receptor MT3 de melatonina
CN109293652B (zh) * 2017-07-24 2021-10-22 四川科伦博泰生物医药股份有限公司 一种取代的噻唑衍生物及其用途
CN109651358B (zh) * 2017-10-11 2023-04-07 上海迪诺医药科技有限公司 4-氨基吡啶衍生物、其药物组合物、制备方法及应用
WO2020083957A1 (en) 2018-10-24 2020-04-30 Leadxpro Ag Functionalized aminotriazines
CA3126735A1 (en) 2019-01-11 2020-07-16 Omeros Corporation Methods and compositions for treating cancer
EP4466267A1 (en) * 2022-01-19 2024-11-27 LeadXpro AG Functionalized aminothiazoles
GB2615307A (en) * 2022-01-28 2023-08-09 Adorx Therapeutics Ltd Antagonist compounds

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2677356B1 (fr) * 1991-06-05 1995-03-17 Sanofi Sa Derives heterocycliques d'acylamino-2 thiazoles-5 substitues, leur preparation et compositions pharmaceutiques en contenant.
WO1999064418A1 (en) * 1998-06-05 1999-12-16 Novartis Ag Aryl pyridinyl thiazoles
JP2000281685A (ja) * 1999-01-28 2000-10-10 Takeda Chem Ind Ltd チアゾロピリミジン化合物、その製造法および用途
EP1224185B1 (en) * 1999-10-27 2005-11-30 Novartis AG Thiazole and imidazo[4,5-b]pyridine compounds and their pharmaceutical use
GB0028383D0 (en) * 2000-11-21 2001-01-03 Novartis Ag Organic compounds
JP2002302445A (ja) * 2001-02-02 2002-10-18 Takeda Chem Ind Ltd Ｊｎｋ阻害剤
GB0123589D0 (en) * 2001-10-01 2001-11-21 Syngenta Participations Ag Organic compounds
WO2003039451A2 (en) * 2001-11-08 2003-05-15 Fujisawa Pharmaceutical Co., Ltd. Thiazole pyridazinones as adenosine antagonists

Also Published As

Publication number Publication date
ATE388147T1 (de) 2008-03-15
JP2007518767A (ja) 2007-07-12
DE602005005161D1 (de) 2008-04-17
GB0401336D0 (en) 2004-02-25
KR20060129276A (ko) 2006-12-15
AU2005206290A1 (en) 2005-08-04
PL1709036T3 (pl) 2008-08-29
CA2553010A1 (en) 2005-08-04
EP1709036A1 (en) 2006-10-11
PT1709036E (pt) 2008-05-28
CN1910178A (zh) 2007-02-07
EP1709036B1 (en) 2008-03-05
BRPI0506927A (pt) 2007-06-05
WO2005070926A1 (en) 2005-08-04
CN1910178B (zh) 2010-06-02
RU2006130002A (ru) 2008-02-27
US20090233938A1 (en) 2009-09-17
RU2374242C2 (ru) 2009-11-27
DE602005005161T2 (de) 2009-03-19
ES2300985T3 (es) 2008-06-16

Similar Documents

Publication Publication Date Title
EP1339711B1 (en) Aminothiazoles and their use as adenosine receptor antagonists
AU2005206290B2 (en) Thiazole derivatives as A2b antagonists
AU2005270314B2 (en) Pyrazole derivatives for treating conditions mediated by activation of the adenosine A2b or A3 receptor
MXPA06008297A (en) Thiazole derivatives as a2b antagonists
AU2005270305B2 (en) Piperazine derivatives with CCR3 inhibiting activity
AU2005270306B2 (en) Organic compounds
AU2006200584A1 (en) Aminothiazoles and their use as adenosine receptor antagonists
AU2005211491B2 (en) Pyrrolidine derivatives acting as CCR3-receptor antagonists
AU2005270308A1 (en) Azetidine derivatives as CCR-3 receptor antagonists

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired